



HAL
open science

Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases – An Ongoing Tale

Arnaud Bourdin, Carey Suehs, Thomas Colby, Isabelle Vachier, Nicolas
Molinari, Micaela Romagnoli

► To cite this version:

Arnaud Bourdin, Carey Suehs, Thomas Colby, Isabelle Vachier, Nicolas Molinari, et al.. Reply to Wand et al.: Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases – An Ongoing Tale. *American Journal of Respiratory and Critical Care Medicine*, 2019, 201 (2), pp.260-261. 10.1164/rccm.201909-1736LE . hal-02293644

HAL Id: hal-02293644

<https://hal.science/hal-02293644>

Submitted on 22 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Arnaud Bourdin, M.D., Ph.D.
Carey M. Suehs, Ph.D.
Centre Hospitalier Universitaire de Montpellier
Montpellier, France

Thomas V. Colby, M.D.
Mayo Clinic
Scottsdale, Arizona

Isabelle Vachier, Ph.D.
Nicolas Molinari, Ph.D.
Centre Hospitalier Universitaire de Montpellier
Montpellier, France

Reply to Wand *et al.*

Micaela Romagnoli, M.D., Ph.D.*
Azienda ULSS n. 2 Marca Trevigiana
Treviso, Italy

From the Authors:

We read with interest the letter to the editor from Wand and colleagues, who highlighted some concerns about the findings in our recent article, which showed a poor concordance between lung histology from sequential transbronchial lung cryobiopsies (TBLC) and surgical lung biopsies (SLB) obtained prospectively from the same patient during the same surgical procedure.

We obviously agree with the authors regarding the critical importance of multidisciplinary assessments (MDAs) in the diagnostic evaluation of interstitial lung diseases (ILDs) (1, 2), despite the reported low agreement among MDAs for ILDs that are not idiopathic pulmonary fibrosis (3). However, the role of MDAs was not the main focus of our study. Our goal was to assess the concordance of pathological diagnoses *per se* obtained by two different procedures (TBLC and SLB) performed in the same patient, blinded to any clinical information—something that has never been done before. We do believe that our blinded histology approach was somewhat artificial, and we agree that it was outside the routine clinical workflow, as clearly stated in our article (1). However, we

Ⓒ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.201909-1736LE on

also believe that this was the only way to compare pathological outcomes from the two techniques while avoiding significant bias.

We had considered assessing the concordance between the blinded pathologist and the other two local pathologists but concluded that this was not an appropriate comparison because the methodologies used in these two contexts were different (e.g., blinded vs. nonblinded). In fact, the two nonblinded pathologists were not only informed about clinical and radiological information but were also “biased” by the fact that they were simultaneously assessing both TBLC and SLB for the same patient at the same time. Although the agreement level of 57.1% Wand and colleagues calculated from the provided data is correct, we considered this calculation problematic because the two approaches (blinded vs. nonblinded) cannot be directly compared, and we decided not to include it in our report. If anything, this would indicate that all pathologists involved held to a high diagnostic standard.

We also considered involving two or more blinded pathologists but, based on discussions with the statistician (N.M.), concluded that the addition of another blinded pathologist would have introduced more confusion than improvement in data readability. Indeed, the community should keep in mind that concordance among experts in this domain is traditionally fair to poor, and the cases involved are inherently difficult to diagnose.

Our study demonstrates that in several cases, TBLC alone would have led to a completely different diagnosis. One of these cases, chronic lymphocytic leukemia (at blinded TBLC) versus desquamative interstitial pneumonia (at SLB), can be discussed as an insightful example of poor concordance. Clearly, this case is related to a sampling issue and would likely have been sorted out in MDA discussions even with the TBLC alone (considering the patient’s history of smoking and lymphoproliferative disease, among other factors).

The suggestion by Wand and colleagues to discuss either sampling technique in a separate MDA is interesting. We are planning to conduct such an analysis and will report our findings.

In conclusion, we definitely do not completely reject the role of TBLC in the assessment of ILDs. However, our findings suggest that for now, TBLC should not be considered interchangeable with SLB in the management of ILDs (1, 2). Although we all agree that we need further studies and data, we suggest that TBLC in patients with ILD should not be encouraged in routine clinical practice (4) and should only be performed in the setting of registered, ethically approved clinical trials involving clearly informed patients (5), or in patients who deliberately refuse or are not suitable for SLB. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Arnaud Bourdin, M.D., Ph.D.
Carey M. Suehs, Ph.D.
Centre Hospitalier Universitaire de Montpellier
Montpellier, France

Thomas V. Colby, M.D.
Mayo Clinic
Scottsdale, Arizona

Isabelle Vachier, Ph.D.
Nicolas Molinari, Ph.D.
Centre Hospitalier Universitaire de Montpellier
Montpellier, France

Micaela Romagnoli, M.D., Ph.D.*
Azienda ULSS n. 2 Marca Trevigiana
Trevise, Italy

*Corresponding author (e-mail: miki.romagnoli@gmail.com).

References

1. Romagnoli M, Colby TV, Berthet JP, Gamez AS, Mallet JP, Serre I, *et al*. Poor concordance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in the diagnosis of diffuse interstitial lung diseases. *Am J Respir Crit Care Med* 2019;199:1249–1256.
2. Romagnoli M, Colby TV, Suehs CM, Vachier I, Molinari N, Bourdin A. Cryobiopsy compared with surgical lung biopsy in ILD: reply to Maldonado *et al.*, Froidure *et al.*, Bendstrup *et al.*, Agarwal *et al.*, Richeldi *et al.*, Rajchgot *et al.*, and Quadrelli *et al*. *Am J Respir Crit Care Med* 2019;200:944–946.
3. Walsh SLF, Wells AU, Desai SR, Poletti V, Piciocchi S, Dubini A, *et al*. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. *Lancet Respir Med* 2016;4:557–565.
4. Raghu G, Lederer DJ, Rabe KF. Cryobiopsy for interstitial lung disease: the heat is on. *Am J Respir Crit Care Med* 2019;199:1183–1184.
5. Richeldi L, Cottin V, Brown KK, Flaherty KR, Johansson KA, Travis WD, *et al*. Which biopsy to diagnose interstitial lung disease? A call for evidence and unity. *Am J Respir Crit Care Med* 2019;200:941–942.